AstraZeneca expands US manufacturing footprint to accelerate ambitions in next-generation cell therapy discovery and development
06 Février 2024 - 3:00PM
Business Wire
New facility in Rockville, Maryland will
focus on manufacturing for critical cancer trials and launch of its
commercial cell therapy platforms
AstraZeneca is investing $300 million in a state-of-the-art
facility in Rockville, MD to launch its life-saving cell therapy
platforms in the US for critical cancer trials and future
commercial supply. More than 150 new highly skilled jobs will be
created to initially focus on manufacturing T-cell therapies to
enable clinical trials to be conducted around the world. Over time,
the site may expand its focus to support other disease areas.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240206590080/en/
New AstraZeneca facility in Rockville,
Maryland (Photo: Business Wire)
The site represents the latest investment in cell therapy for
AstraZeneca following collaborations with Quell therapeutics,
AbelZeta, Cellectis, and the acquisition of Neogene
Therapeutics.
Pam Cheng, Executive Vice President of Global Operations &
IT and Chief Sustainability Officer, AstraZeneca, said: “We are
incredibly excited that more than 150 new highly skilled jobs are
being created to bring our scientific work and therapies to
clinical trials which could transform the lives of patients around
the world. This new $300 million investment will accelerate our
ambition to make next-generation cell therapy a reality, ensuring
that we are ready to scale and meet the demands of patients.”
The facility in Rockville, MD is located less than five miles
away from one of the company’s five global R&D centers and sits
within the booming life sciences corridor in Maryland. With close
proximity to several universities, the life sciences ecosystem
provides an attractive environment for recruiting new and
experienced talent.
Maryland Governor Wes Moore said: “AstraZeneca and the State of
Maryland share a deep commitment to innovation. It makes us the
perfect pairing for this next-generation cell therapy facility.
This significant investment in our life sciences sector will help
maintain Maryland’s leadership in the industry and sharpen our
competitive edge. We are deeply grateful for AstraZeneca’s
partnership and continued commitment to our state.”
The Rockville facility will join AstraZeneca’s global
manufacturing and supply network of nearly 30 manufacturing and
supply sites in 16 countries, which are either currently
operational or under development across the company. In the US,
AstraZeneca’s manufacturing sites focus on the production of small
molecules and biologics, harnessing leading pharmaceutical
technology and development. Together, the US manufacturing sites
employ more than 2,600 full-time employees and deliver more than 9
billion doses of medicines annually.
Notes
AstraZeneca in oncology cell therapy
AstraZeneca is building a cell therapy portfolio that aims to
empower and equip the immune system’s T-cells to more effectively
fight cancer. The company's research teams are exploring new ways
to target and arm CAR-Ts to increase their effectiveness in solid
tumors by overcoming the immune-suppressive tumor microenvironment.
Looking to the future, AstraZeneca is working to engineer
next-generation cell therapies, where physicians could potentially
select from a library of off-the-shelf patient-ready therapies
already developed from the cells of healthy donors.
AstraZeneca is advancing multiple armoured autologous CAR-T,
including Glypican 3 (GPC3) targeting CAR-Ts in hepatocellular
carcinoma. AZD5851, currently in Phase I, is being developed
globally, and AZD7003 / C-CAR031 is being co-developed with
AbelZeta in China where it is under evaluation in an Investigator
Initiated Trial (IIT).
Also, in early development is AZD6422, a novel Claudin 18.2
targeting CAR-T currently being evaluated in solid tumors in an IIT
in China, in collaboration with AbelZeta, and AZD0754, a
preclinical stage STEAP2 targeting CAR-T that will be investigated
in prostate cancer.
Beyond this, the company is advancing a pipeline of novel T-cell
receptor therapies (TCR-Ts) through Neogene Therapeutics, a wholly
owned subsidiary of AstraZeneca. This includes NT-125, a fully
individualized TCR-T, NT-175, a TP53 mutant targeting TCR-T and
NT-112, a KRAS mutant targeting TCR-T, all in Phase I clinical
trials in solid tumors.
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company
that focuses on the discovery, development and commercialization of
prescription medicines in Oncology, Rare Diseases and
BioPharmaceuticals, including Cardiovascular, Renal &
Metabolism, and Respiratory & Immunology. Based in Cambridge,
UK, AstraZeneca operates in over 100 countries and its innovative
medicines are used by millions of patients worldwide. Please visit
www.astrazeneca-us.com and follow us on social media
@AstraZeneca.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240206590080/en/
Media Inquiries Brendan McEvoy, +1 302 885 2677
US Media Mailbox: usmediateam@astrazeneca.com
AstraZeneca (NASDAQ:AZN)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
AstraZeneca (NASDAQ:AZN)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024